India Unit Of Sanofi-Aventis Told By WHO 5-Disease Vaccine Has Problem
This article was originally published in PharmAsia News
Executive Summary
The Indian subsidiary of French drug maker Sanofi-Aventis has been told by the United Nations it was suspending purchase and use of the Shan5 vaccine for five diseases, including tetanus
You may also be interested in...
WHO's Product Recall Order For Shantha Biotech's Vaccine Puts Sanofi Aventis In Crisis Management Mode; Vows To Resume Supplies By End Of 2010
MUMBAI - French drug maker Sanofi Aventis is faced with an unexpected crisis situation over large quantities of product recall ordered by the World Health Organization for pediatric pentavalent vaccines manufactured by its newly acquired Indian vaccines unit - Shantha Biotechnics
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.